



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07H 21/04, C07K 13/00 C12N 1/00, 5/10, 15/62 C12N 15/63	A1	(11) International Publication Number: WO 94/02502 (43) International Publication Date: 3 February 1994 (03.02.94)
(21) International Application Number: PCT/US93/06913 (22) International Filing Date: 23 July 1993 (23.07.93) (30) Priority data: 07/921,848 28 July 1992 (28.07.92) US (71) Applicant: GENETICS INSTITUTE, INC. [US/US]; 87 CambridgePark Drive, Cambridge, MA 02140 (US). (72) Inventors: McCOY, John ; 63 Pine Ridge Road, Reading, MA 01867 (US). LAVALLIE, Edward, R. ; 90 Green Meadow Drive, Tewksbury, MA 01876 (US). (74) Agent: MEINERT, Maureen, C.; Legal Affairs, Genetics Institute, Inc., 87 CambridgePark Drive, Cambridge, MA 02140 (US).		(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: PEPTIDE AND PROTEIN FUSIONS TO THIOREDOXIN AND THIOREDOXIN-LIKE MOLECULES (57) Abstract This invention provides a fusion molecule comprising a DNA sequence encoding a thioredoxin-like protein fused to the DNA sequence encoding a selected heterologous peptide or protein. The peptide or protein may be fused to the amino terminus of the thioredoxin-like molecule, the carboxyl terminus of the thioredoxin-like molecule, or within the thioredoxin-like molecule, for example at the active-site loop of said molecule. Expression of this fusion molecule under the control of a regulatory sequence capable of directing its expression in a desired host cell, produces high levels of stable and soluble fusion protein. The fusion protein, located in the bacterial cytoplasm, may be selectively released from the cell by osmotic shock or freeze/thaw procedures. It may be optionally cleaved to liberate the soluble, correctly folded heterologous protein from the thioredoxin-like portion.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NE	Niger
BE	Belgium	GN	Guinea	NL	Netherlands
BF	Burkina Faso	GR	Greece	NO	Norway
BG	Bulgaria	HU	Hungary	NZ	New Zealand
BJ	Benin	IE	Ireland	PL	Poland
BR	Brazil	IT	Italy	PT	Portugal
BY	Belarus	JP	Japan	RO	Romania
CA	Canada	KP	Democratic People's Republic of Korea	RU	Russian Federation
CF	Central African Republic	KR	Republic of Korea	SD	Sudan
CG	Congo	KZ	Kazakhstan	SE	Sweden
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovak Republic
CM	Cameroon	LU	Luxembourg	SN	Senegal
CN	China	LV	Latvia	TD	Chad
CS	Czechoslovakia	MC	Monaco	TG	Togo
CZ	Czech Republic	MG	Madagascar	UA	Ukraine
DE	Germany	ML	Mali	US	United States of America
DK	Denmark	MN	Mongolia	UZ	Uzbekistan
ES	Spain			VN	Viet Nam
FI	Finland				

PEPTIDE AND PROTEIN FUSIONS TO THIOREDOXIN AND
THIOREDOXIN-LIKE MOLECULES

5 The present invention relates generally to the production
of fusion proteins in prokaryotic and eukaryotic cells. More
specifically, the invention relates to the expression in host
cells of recombinant fusion sequences comprising thioredoxin or
thioredoxin-like sequences fused to sequences for selected
10 heterologous peptides or proteins, and the use of such fusion
molecules to increase the production, activity, stability or
solubility of recombinant proteins and peptides.

Background of the Invention

15 Many peptides and proteins can be produced via recombinant
means in a variety of expression systems, e.g., various strains
of bacterial, fungal, mammalian or insect cells. However, when
bacteria are used as host cells for heterologous gene expression,
several problems frequently occur.

20 For example, heterologous genes encoding small peptides are
often poorly expressed in bacteria. Because of their size, most
small peptides are unable to adopt stable, soluble conformations
and are subject to intracellular degradation by proteases and
peptidases present in the host cell. Those small peptides which
25 do manage to accumulate when directly expressed in E. coli or
other bacterial hosts are usually found in the insoluble or
"inclusion body" fraction, an occurrence which renders them
almost useless for screening purposes in biological or
biochemical assays.

30 Moreover, even if small peptides are not produced in
inclusion bodies, the production of small peptides by recombinant
means as candidates for new drugs or enzyme inhibitors encounters
further problems. Even small linear peptides can adopt an
enormous number of potential structures due to their degrees of
35 conformational freedom. Thus a small peptide can have the
'desired' amino-acid sequence and yet have very low activity in
an assay because the 'active' peptide conformation is only one

of the many alternative structures adopted in free solution. This presents another difficulty encountered in producing small heterologous peptides recombinantly for effective research and therapeutic use.

5 Inclusion body formation is also frequently observed when the genes for heterologous proteins are expressed in bacterial cells. These inclusion bodies usually require further manipulations in order to solubilize and refold the heterologous protein, with conditions determined empirically and with
10 uncertainty in each case.

If these additional procedures are not successful, little to no protein retaining bioactivity can be recovered from the host cells. Moreover, these additional processes are often technically difficult and prohibitively expensive for practical
15 production of recombinant proteins for therapeutic, diagnostic or other research uses.

To overcome these problems, the art has employed certain peptides or proteins as fusion "partners" with a desired heterologous peptide or protein to enable the recombinant
20 expression and/or secretion of small peptides or larger proteins as fusion proteins in bacterial expression systems. Among such fusion partners are included lacZ and trpE fusion proteins, maltose-binding protein fusions, and glutathione-S-transferase fusion proteins [See, generally, Current Protocols in Molecular
25 Biology, Vol. 2, suppl. 10, publ. John Wiley and Sons, New York, NY, pp. 16.4.1-16.8.1 (1990); and Smith et al, Gene, 67:31-40 (1988)]. As another example, U. S. Patent 4,801,536 describes the fusion of a bacterial flagellin protein to a desired protein to enable the production of a heterologous gene in a bacterial
30 cell and its secretion into the culture medium as a fusion protein.

However, often fusions of desired peptides or proteins to other proteins (i.e., as fusion partners) at the amino- or carboxyl- termini of these fusion partner proteins have other
35 potential disadvantages. Experience in E. coli has shown that

a crucial factor in obtaining high levels of gene expression is the efficiency of translational initiation. Translational initiation in E. coli is very sensitive to the nucleotide sequence surrounding the initiating methionine codon of the desired heterologous peptide or protein sequence, although the rules governing this phenomenon are not clear. For this reason, fusions of sequences at the amino-terminus of many fusion partner proteins affects expression levels in an unpredictable manner. In addition there are numerous amino- and carboxy-peptidases in E. coli which degrade amino- or carboxyl-terminal peptide extensions to fusion partner proteins so that a number of the known fusion partners have a low success rate for producing stable fusion proteins.

The purification of proteins produced by recombinant expression systems is often a serious challenge. There is a continuing requirement for new and easier methods to produce homogeneous preparations of recombinant proteins, and yet a number of the fusion partners currently used in the art possess no inherent properties that would facilitate the purification process. Therefore, in the art of recombinant expression systems, there remains a need for new compositions and processes for the production and purification of stable, soluble peptides and proteins for use in research, diagnostic and therapeutic applications.

Summary of the Invention

In one aspect, the present invention provides a fusion sequence comprising a thioredoxin-like protein sequence fused to a selected heterologous peptide or protein. The peptide or protein may be fused to the amino terminus of the thioredoxin-like sequence, the carboxyl terminus of the thioredoxin-like sequence, or within the thioredoxin-like sequence (e.g., within the active-site loop of thioredoxin). The fusion sequence according to this invention may optionally contain a linker peptide between the thioredoxin-like sequence and the selected

peptide or protein. This linker provides, where needed, a selected cleavage site or a stretch of amino acids capable of preventing steric hindrance between the thioredoxin-like molecule and the selected peptide or protein.

5 As another aspect, the present invention provides a DNA molecule encoding the fusion sequence defined above in association with, and under the control of, an expression control sequence capable of directing the expression of the fusion protein in a desired host cell.

10 Still a further aspect of the invention is a host cell transformed with, or having integrated into its genome, a DNA sequence comprising a thioredoxin-like DNA sequence fused to the DNA sequence of a selected heterologous peptide or protein. This fusion sequence is desirably under the control of an expression
15 control sequence capable of directing the expression of a fusion protein in the cell.

As yet another aspect, there is provided a novel method for increasing the expression of soluble recombinant proteins. The method includes culturing under suitable conditions the above-
20 described host cell to produce the fusion protein.

In one embodiment of this method, if the resulting fusion protein is cytoplasmic, the cell can be lysed by conventional means to obtain the soluble fusion protein. More preferably in the case of cytoplasmic fusion proteins, the method includes
25 releasing the fusion protein from the host cell by applying osmotic shock or freeze/thaw treatments to the cell. In this case the fusion protein is selectively released from the interior of the cell via the zones of adhesion that exist between the inner and outer membranes of E. coli. The fusion protein is then
30 purified by conventional means. In still another embodiment, if a secretory leader is employed in the fusion protein construct, the fusion protein can be recovered from a periplasmic extract or from the cell culture medium. As yet a further step in the above methods, the desired protein can be cleaved from fusion
35 with the thioredoxin-like protein by conventional means.

Other aspects and advantages of the present invention will be apparent upon consideration of the following detailed description of preferred embodiments thereof.

5 Summary of the Drawings

Fig. 1 illustrates the DNA sequence of the expression plasmid pALtrxA/EK/IL11ΔPro-581 (SEQ ID NO:13) and the amino acid sequence for the fusion protein therein (SEQ ID NO:14), described in Example 1.

10 Fig. 2 illustrates the DNA sequence (SEQ ID NO:15) and amino acid sequence (SEQ ID NO:16) of the macrophage inhibitory protein-1α (MIP-1α) protein used in the construction of a thioredoxin fusion protein described in Example 3.

15 Fig. 3 illustrates the DNA sequence (SEQ ID NO:17) and amino acid sequence (SEQ ID NO:18) of the bone morphogenetic protein-2 (BMP-2) protein used in the construction of a thioredoxin fusion protein described in Example 4.

20 Fig. 4 is a schematic drawing illustrating the insertion of an enterokinase cleavage site into the active-site loop of E. coli thioredoxin (trxA) described in Example 5.

Fig. 5 is a schematic drawing illustrating random peptide insertions into the active-site loop of E. coli thioredoxin (trxA) described in Example 5.

25 Fig. 6 illustrates the DNA sequence (SEQ ID NO:19) and amino acid sequence (SEQ ID NO:20) of the human interleukin-6 (IL6) protein used in the construction of a thioredoxin fusion protein described in Example 6.

30 Fig. 7 illustrates the DNA sequence (SEQ ID NO:23) and amino acid sequence (SEQ ID NO:24) of the M-CSF protein used in the construction of a thioredoxin fusion protein described in Example 7.

Detailed Description of the Invention

35 The methods and compositions of the present invention permit the production of large amounts of heterologous peptides or proteins in a stable, soluble form in certain host cells which

normally express limited amounts of such peptides or proteins. The present invention produces fusion proteins which retain the desirable characteristics of a thioredoxin-like protein (i.e. stability, solubility and a high level of expression). The invention also allows a small peptide insert into an internal region of the thioredoxin-like sequence (e.g. the active site loop of thioredoxin) to be accessible on the surface of the molecule. These fusion proteins also permit a peptide or protein fused at the free ends of the thioredoxin-like protein to achieve its desired conformation.

According to the present invention, the DNA sequence encoding a heterologous peptide or protein selected for expression in a recombinant system is desirably fused to a thioredoxin-like DNA sequence for expression in the host cell. A thioredoxin-like DNA sequence is defined herein as a DNA sequence encoding a protein or fragment of a protein characterized by an amino acid sequence having at least 30% homology with the amino acid sequence of E. coli thioredoxin (SEQ ID NO:22). Alternatively, a thioredoxin-like DNA sequence is defined herein as a DNA sequence encoding a protein or fragment of a protein characterized by a having a three dimensional structure substantially similar to that of human or E. coli thioredoxin (SEQ ID NO: 22) and by containing an active site loop. The DNA sequence of glutaredoxin is an example of a thioredoxin-like DNA sequence which encodes a protein that exhibits such substantial similarity in three-dimensional conformation and contains a Cys....Cys active site loop. The amino acid sequence of E. coli thioredoxin is described in H. Eklund et al, EMBO J., 3:1443-1449 (1984). The three-dimensional structure of E. coli thioredoxin is depicted in Fig. 2 of A. Holmgren, J. Biol. Chem., 264:13963-13966 (1989). Fig. 1 below nucleotides 2242-2568 contains a DNA sequence encoding the E. coli thioredoxin protein [Lim et al, J. Bacteriol., 163:311-316 (1985)] (SEQ ID NO:21). A comparison of the three dimensional structures of E. coli thioredoxin and glutaredoxin is published

in Xia, Protein Science I:310-321 (1992). These four publications are incorporated herein by reference for the purpose of providing information on thioredoxin-like proteins that is known to one of skill in the art.

5 As the primary example of a thioredoxin-like protein useful in this invention, E. coli thioredoxin (SEQ ID NO:21 and SEQ ID NO:22) has the following characteristics. E. coli thioredoxin is a small protein, only 11.7 kD, and can be expressed to high levels (>10%, corresponding to a concentration of 15 uM if cells
10 are lysed at 10 A₅₅₀/ml). The small size and capacity for high expression of the protein contributes to a high intracellular concentration. E. coli thioredoxin is further characterized by a very stable, tight structure which can minimize the effects on overall structural stability caused by fusion to the desired
15 peptide or proteins.

 The three dimensional structure of E. coli thioredoxin is known and contains several surface loops, including a unique Cys....Cys active site loop between residues Cys₃₃ and Cys₃₆ which protrudes from the body of the protein. This Cys....Cys active
20 site loop is an identifiable, accessible surface loop region and is not involved in any interactions with the rest of the protein that contribute to overall structural stability. It is therefore a good candidate as a site for peptide insertions. Both the amino- and carboxyl-termini of E. coli thioredoxin are on the
25 surface of the protein, and are readily accessible for fusions. Human thioredoxin, glutaredoxin and other thioredoxin-like molecules also contain this Cys....Cys active site loop.

E. coli thioredoxin is also stable to proteases. Thus, E. coli thioredoxin may be desirable for use in E. coli expression
30 systems, because as an E. coli protein it is characterized by stability to E. coli proteases. E. coli thioredoxin is also stable to heat up to 80°C and to low pH. Other thioredoxin-like proteins encoded by thioredoxin-like DNA sequences useful in this invention share the homologous amino acid sequences, and
35 similar physical and structural characteristics. Thus, DNA

sequences encoding other thioredoxin-like proteins may be used in place of E. coli thioredoxin (SEQ ID NO:21 and SEQ ID NO:22) according to this invention. For example, the DNA sequence encoding other species' thioredoxin, e.g., human thioredoxin, have been employed by these inventors in the compositions and methods of this invention. Human thioredoxin has a three-dimensional structure that is virtually superimposable on E. coli's three-dimensional structure, as determined by comparing the NMR structures of the two molecules. Human thioredoxin also contains an active site loop structurally and functionally equivalent to the Cys....Cys active site loop found in the E. coli protein. Human IL-11 fused in frame to the carboxyl terminus of human thioredoxin (i.e., a human thioredoxin/IL-11 fusion) exhibited the same expression characteristics as the E. coli thioredoxin/IL-11 fusion exemplified in Examples 1-2. Consequently, human thioredoxin is a thioredoxin-like molecule and can be used in place of or in addition to E. coli thioredoxin in the production of protein and small peptides in accordance with the method of this invention. Insertions into the human thioredoxin active site loop and on the amino terminus may be as well tolerated as those in E. coli thioredoxin.

Other thioredoxin-like sequences which may be employed in this invention include all or portions of the protein glutaredoxin and various species' homologs thereof [A. Holmgren, cited above]. Although E. coli glutaredoxin and E. coli thioredoxin share less than 20% amino acid homology, the two proteins do have conformational and functional similarities [Eklund et al, EMBO J., 3:1443-1449 (1984)] and glutaredoxin contains an active site loop structurally and functionally equivalent to the Cys....Cys active site loop of E. coli thioredoxin. Glutaredoxin is therefore a thioredoxin-like molecule as herein defined.

The DNA sequence encoding protein disulfide isomerase (PDI), or that portion thereof containing the thioredoxin-like domain, and its various species' homologs [J. E. Edman et al, Nature,

317:267-270 (1985)] may also be employed as a thioredoxin-like DNA sequence, since a repeated domain of PDI shares >30% homology with E. coli thioredoxin and that repeated domain exhibits a three-dimensional structure substantially similar to that of E. coli thioredoxin and contains an active site loop structurally and functionally equivalent to the Cys....Cys active site loop of E. coli thioredoxin. These two publications are incorporated herein by reference for the purpose of providing information on glutaredoxin and PDI which is known and available to one of skill in the art.

Similarly the DNA sequence encoding phosphoinositide-specific phospholipase C (PI-PLC), fragments thereof and various species' homologs thereof [C. F. Bennett et al, Nature, 334:268-270 (1988)] may also be employed in the present invention as a thioredoxin-like sequence based on their amino acid sequence homology with E. coli thioredoxin, or alternatively based on similarity in three-dimensional conformation and the presence of an active site loop structurally and functionally equivalent to the Cys....Cys active site loop of E. coli thioredoxin. All or a portion of the DNA sequence encoding an endoplasmic reticulum protein, such as ERp72, or various species homologs thereof are also included as thioredoxin-like DNA sequences for the purposes of this invention [R. A. Mazzaella et al, J. Biol. Chem., 265:1094-1101 (1990)] based on amino acid sequence homology, or alternatively based on similarity in three-dimensional conformation and the presence of an active site loop structurally and functionally equivalent to the Cys....Cys active site loop of E. coli thioredoxin. Another thioredoxin-like sequence is a DNA sequence which encodes all or a portion of an adult T-cell leukemia-derived factor (ADF) or other species homologs thereof [N. Wakasugi et al, Proc. Natl. Acad. Sci., USA, 87:8282-8286 (1990)]. ADF is now believed to be human thioredoxin. These three publications are incorporated herein by reference for the purpose of providing information on PI-PLC, ERp72, and ADF which are known and available to one of skill in the art.

It is expected from the definition of thioredoxin-like DNA sequence used above that other sequences not specifically identified above, or perhaps not yet identified or published, may be thioredoxin-like sequences either based on the 30% amino acid sequence homology to E. coli thioredoxin or based on having three-dimensional structures substantially similar to E. coli or human thioredoxin and having an active site loop functionally and structurally equivalent to the Cys....Cys active site loop of E. coli thioredoxin. One skilled in the art can determine whether a molecule has these latter two characteristics by comparing its three-dimensional structure, as analyzed for example by x-ray crystallography or 2 dimensional NMR spectroscopy, with the published three-dimensional structure for E. coli thioredoxin and by analyzing the amino acid sequence of the molecule to determine whether it contains an active site loop that is structurally and functionally equivalent to the Cys....Cys active site loop of E. coli thioredoxin. By "substantially similar" in three-dimensional structure or conformation these inventors mean as similar to E. coli thioredoxin as is glutaredoxin. Based on the above description, one of skill in the art will be able to select and identify, or, if desired, modify, a thioredoxin-like DNA sequence for use in this invention without resort to undue experimentation. For example, simple point mutations made to portions of native thioredoxin or native thioredoxin-like sequences which do not effect the structure of the resulting molecule are alternative thioredoxin-like sequences, as are allelic variants of native thioredoxin or native thioredoxin-like sequences.

DNA sequences which hybridize to the sequence for E. coli thioredoxin (SEQ ID NO:21) or its structural homologs under either stringent or relaxed hybridization conditions also encode thioredoxin-like proteins for use in this invention. An example of one such stringent hybridization condition is hybridization at 4XSSC at 65°C, followed by a washing in 0.1XSSC at 65°C for an hour. Alternatively an exemplary stringent hybridization

condition is in 50% formamide, 4XSSC at 42°C. Examples of non-stringent hybridization conditions are 4XSSC at 50°C or hybridization with 30-40% formamide at 42°C. The use of all such thioredoxin-like sequences are believed to be encompassed in this invention.

Construction of a fusion sequence of the present invention, which comprises the DNA sequence of a selected peptide or protein and the DNA sequence of a thioredoxin-like sequence, employs conventional genetic engineering techniques [see, Sambrook et al, Molecular Cloning. A Laboratory Manual., Cold Spring Harbor Laboratory, Cold Spring Harbor, New York (1989)]. Fusion sequences may be prepared in a number of different ways. For example, the selected heterologous protein may be fused to the amino terminus of the thioredoxin-like molecule. Alternatively, the selected protein sequence may be fused to the carboxyl terminus of the thioredoxin-like molecule. Small peptide sequences could also be fused to either of the above-mentioned positions of the thioredoxin-like sequence to produce them in a structurally unconstrained manner.

This fusion of a desired heterologous peptide or protein to the thioredoxin-like protein increases the stability of the peptide or protein. At either the amino or carboxyl terminus, the desired heterologous peptide or protein is fused in such a manner that the fusion does not destabilize the native structure of either protein. Additionally, fusion to the soluble thioredoxin-like protein improves the solubility of the selected heterologous peptide or protein.

It may be preferred for a variety of reasons that peptides be fused within the active site loop of the thioredoxin-like molecule. The face of thioredoxin surrounding the active site loop has evolved, in keeping with the protein's major function as a nonspecific protein disulfide oxido-reductase, to be able to interact with a wide variety of protein surfaces. The active site loop region is found between segments of strong secondary structure and offers many advantages for peptide fusions. A

small peptide inserted into the active-site loop of a thioredoxin-like protein is present in a region of the protein which is not involved in maintaining tertiary structure. Therefore the structure of such a fusion protein is stable.

5 Previous work has shown that E. coli thioredoxin can be cleaved into two fragments at a position close to the active site loop, and yet the tertiary interactions stabilizing the protein remain.

The active site loop of E. coli thioredoxin (SEQ ID NO:22) has the sequence $\text{NH}_2\ldots\text{Cys}_{33}\text{-Gly-Pro-Cys}_{34}\ldots\text{COOH}$. Fusing a selected peptide with a thioredoxin-like protein in the active loop portion of the protein constrains the peptide at both ends, reducing the degrees of conformational freedom of the peptide, and consequently reducing the number of alternative structures taken by the peptide. The inserted peptide is bound at each end by cysteine residues, which may form a disulfide linkage to each other as they do in native thioredoxin and further limit the conformational freedom of the inserted peptide.

10
15

Moreover, this invention places the peptide on the surface of the thioredoxin-like protein. Thus the invention provides a distinct advantage for use of the peptides in screening for bioactive peptide conformations and other assays by presenting peptides inserted in the active site loop in this structural context.

20

Additionally the fusion of a peptide into the loop protects it from the actions of E. coli amino- and carboxyl-peptidases. Further a restriction endonuclease cleavage site RsrII already exists in the portion of the E. coli thioredoxin DNA sequence (SEQ ID NO:21) encoding the loop region at precisely the correct position for a peptide fusion [see Figure 4]. RsrII recognizes the DNA sequence CGG(A/T)CCG leaving a three nucleotide long 5'-protruding sticky end. DNA bearing the complementary sticky ends will therefore insert at this site in just one orientation.

25
30

A fusion sequence of a thioredoxin-like sequence and a desired protein or peptide sequence according to this invention

35

may optionally contain a linker peptide inserted between the thioredoxin-like sequence and the selected heterologous peptide or protein. This linker sequence may encode, if desired, a polypeptide which is selectably cleavable or digestible by conventional chemical or enzymatic methods. For example, the selected cleavage site may be an enzymatic cleavage site. Examples of enzymatic cleavage sites include sites for cleavage by a proteolytic enzyme, such as enterokinase, Factor Xa, trypsin, collagenase, and thrombin. Alternatively, the cleavage site in the linker may be a site capable of being cleaved upon exposure to a selected chemical, e.g., cyanogen bromide, hydroxylamine, or low pH.

Cleavage at the selected cleavage site enables separation of the heterologous protein or peptide from the thioredoxin fusion protein to yield the mature heterologous peptide or protein. The mature peptide or protein may then be obtained in purified form, free from any polypeptide fragment of the thioredoxin-like protein to which it was previously linked. The cleavage site, if inserted into a linker useful in the fusion sequences of this invention, does not limit this invention. Any desired cleavage site, of which many are known in the art, may be used for this purpose.

The optional linker sequence of a fusion sequence of the present invention may serve a purpose other than the provision of a cleavage site. The linker may also be a simple amino acid sequence of a sufficient length to prevent any steric hindrance between the thioredoxin-like molecule and the selected heterologous peptide or protein.

Whether or not such a linker sequence is necessary will depend upon the structural characteristics of the selected heterologous peptide or protein and whether or not the resulting fusion protein is useful without cleavage. For example, where the thioredoxin-like sequence is a human sequence, the fusion protein may itself be useful as a therapeutic or as a vaccine without cleavage of the selected protein or peptide therefrom.

Alternatively, where the mature protein sequence may be naturally cleaved, no linker may be needed.

5 In one embodiment therefore, the fusion sequence of this invention contains a thioredoxin-like sequence fused directly at its amino or carboxyl terminal end to the sequence of the selected peptide or protein. The resulting fusion protein is thus a soluble cytoplasmic fusion protein. In another embodiment, the fusion sequence further comprises a linker sequence interposed between the thioredoxin-like sequence and the
10 selected peptide or protein sequence. This fusion protein is also produced as a soluble cytoplasmic protein. Similarly, where the selected peptide sequence is inserted into the active site loop region or elsewhere within the thioredoxin-like sequence, a cytoplasmic fusion protein is produced.

15 The cytoplasmic fusion protein can be purified by conventional means. Preferably, as a novel aspect of the present invention, several thioredoxin fusion proteins of this invention may be purified by exploiting an unusual property of thioredoxin. The cytoplasm of E. coli is effectively isolated from the
20 external medium by a cell envelope comprising two membranes, inner and outer, separated from each other by a periplasmic space within which lies a rigid peptidoglycan cell wall. The peptidoglycan wall contributes both shape and strength to the cell. At certain locations in the cell envelope there are "gaps"
25 (called variously Bayer patches, Bayer junctions or adhesion sites) in the peptidoglycan wall where the inner and outer membranes appear to meet and perhaps fuse together. See, M. E. Bayer, J. Bacteriol., 93:1104-1112 (1967) and J. Gen. Microbiol., 53:395-404 (1968). Most of the cellular thioredoxin lies loosely
30 associated with the inner surface of the membrane at these adhesion sites and can be quantitatively expelled from the cell through these adhesion sites by a sudden osmotic shock or by a simple freeze/thaw procedure. See C. A. Lunn and V. P. Pigiet, J. Biol. Chem., 257:11424-11430 (1982) and in "Thioredoxin and
35 Glutaredoxin Systems: Structure and Function, p165-176, (1986)

ed. A. Holmgren et al, Raven Press, New York. To a lesser extent some EF-Tu (elongation factor-Tu) can be expelled in the same way [Jacobson et al, Biochemistry, 15:2297-2302 (1976)], but, with the exception of the periplasmic contents, the vast majority of E. coli proteins cannot be released by these treatments.

Although there have been reports of the release by osmotic shock of a limited number of heterologous proteins produced in the cytoplasm of E. coli [Denefle et al, Gene, 85:499-510 (1989); Joseph-Liauzun et al, Gene, 86:291-295 (1990); Rosenwasser et al, J. Biol. Chem., 265:13066-13073 (1990)], the ability to be so released is a rare and desirable property not shared by the majority of heterologous proteins. Fusion of a selected, desired heterologous protein to thioredoxin as described by the present invention not only enhances its expression, solubility and stability as described above, but may also provide for its release from the cell by osmotic shock or freeze/thaw treatments, greatly simplifying its purification. The thioredoxin portion of the fusion protein in some cases, e.g., with MIP, directs the fusion protein towards the adhesion sites, from where it can be released to the exterior by these treatments.

In another embodiment the present invention may employ another component, that is, a secretory leader sequence, among which many are known in the art, e.g. leader sequences of phoA, MBP, β -lactamase, operatively linked in frame to the fusion protein of this invention to enable the expression and secretion of the mature fusion protein into the bacterial periplasmic space or culture medium. This leader sequence may be fused to the amino terminus of the thioredoxin-like molecule when the selected peptide or protein sequence is fused to the carboxyl terminus or to an internal site within the thioredoxin-like sequence. An optional linker could also be present when the peptide or protein is fused at the carboxyl terminus. It is expected that this fusion sequence construct when expressed in an appropriate host cell would be expressed as a secreted fusion protein rather than a cytoplasmic fusion protein. However stability, solubility and

high expression should characterize fusion proteins produced using any of these alternative embodiments.

This invention is not limited to any specific type of peptide or protein. A wide variety of heterologous (i.e., foreign in reference to the host genome) genes or gene fragments are useful in forming the fusion sequences of the present invention. Any selected, desired DNA sequence could be used. While the compositions and methods of this invention are most useful for peptides or proteins which are not expressed, expressed in inclusion bodies, or expressed in very small amounts in bacterial and yeast hosts, the heterologous, selected, desired peptides or proteins can include any peptide or protein useful for human or veterinary therapy, diagnostic or research applications in any expression system. For example, hormones, cytokines, growth or inhibitory factors, enzymes, modified or wholly synthetic proteins or peptides can be produced according to this invention in bacterial, yeast, mammalian or other eukaryotic cells and expression systems suitable therefor.

In the examples below illustrating this invention, the proteins expressed by this invention include IL-11, MIP-1 α , IL-6, M-CSF, a bone inductive factor called BMP-2, IL-2, IL-3, IL-4, IL-5, LIF, Steel Factor, MIF (macrophage inhibitory factor) and a variety of small peptides of random sequence. These proteins include examples of proteins which, when expressed without a thioredoxin fusion partner, are unstable in E. coli or are found in inclusion bodies.

A variety of DNA molecules incorporating the above-described fusion sequences may be constructed for expressing the selected peptide or protein according to this invention. At a minimum a desirable DNA sequence according to this invention comprises a fusion sequence described above, in association with, and under the control of, an expression control sequence capable of directing the expression of the fusion protein in a desired host cell. For example, where the host cell is an E. coli strain, the DNA molecule desirably contains a promoter which functions in E.

coli, a ribosome binding site, and optionally, a selectable marker gene and an origin of replication if the DNA molecule is extra- chromosomal. Numerous bacterial expression vectors containing these components are known in the art for bacterial
5 expression, and can easily be constructed by standard molecular biology techniques. Similarly known yeast and mammalian cell vectors and vector components may be utilized where the host cell is a yeast cell or a mammalian cell.

The DNA molecules containing the fusion sequences may be
10 further modified to contain different codons to optimize expression in the selected host cell, as is known in the art.

These DNA molecules may additionally contain multiple copies of the thioredoxin-like DNA sequence, with the heterologous protein fused to only one of the DNA sequences, or with the
15 heterologous protein fused to all copies of the thioredoxin-like sequence. It may also be possible to integrate a thioredoxin-like/heterologous peptide or protein-encoding fusion sequence into the chromosome of a selected host to either replace or duplicate a native thioredoxin-like sequence.

20 Host cells suitable for the present invention are preferably bacterial cells. For example, the various strains of E. coli (e.g., HB101, W3110 and strains used in the following examples) are well-known as host cells in the field of biotechnology. E. coli strain GI724, used in the following examples, has been
25 deposited with a United States microorganism depository as described in detail below. Various strains of B. subtilis, Pseudomonas, and other bacteria may also be employed in this method.

Many strains of yeast and other eukaryotic cells known to
30 those skilled in the art may also be useful as host cells for expression of the polypeptides of the present invention. For example, Saccromyces cerevisia strain EGY-40 has been used by these inventors as a host cell in the production of various small peptide/thioredoxin fusions. It could be preferably used instead
35 of E. coli as a host cell in the production of any of the

proteins exemplified herein. Similarly known mammalian cells may also be employed in the expression of these fusion proteins.

To produce the fusion protein of this invention, the host cell is either transformed with, or has integrated into its genome, a DNA molecule comprising a thioredoxin-like DNA sequence fused to the DNA sequence of a selected heterologous peptide or protein, desirably under the control of an expression control sequence capable of directing the expression of a fusion protein. The host cell is then cultured under known conditions suitable for fusion protein production. If the fusion protein accumulates in the cytoplasm of the cell it may be released by conventional bacterial cell lysis techniques and purified by conventional procedures including selective precipitations, solubilizations and column chromatographic methods. If a secretory leader is incorporated into the fusion molecule substantial purification is achieved when the fusion protein is secreted into the periplasmic space or the growth medium.

Alternatively, for cytoplasmic thioredoxin fusion proteins, a selective release from the cell may be achieved by osmotic shock or freeze/thaw procedures. Although final purification is still required for most purposes, the initial purity of fusion proteins in preparations resulting from these procedures is superior to that obtained in conventional whole cell lysates, reducing the number of subsequent purification steps required to attain homogeneity. In a typical osmotic shock procedure, the packed cells containing the fusion protein are resuspended on ice in a buffer containing EDTA and having a high osmolarity, usually due to the inclusion of a solute, such as 20% w/v sucrose, in the buffer which cannot readily cross the cytoplasmic membrane. During a brief incubation on ice the cells plasmolyze as water leaves the cytoplasm down the osmotic gradient. The cells are then switched into a buffer of low osmolarity, and during the osmotic re-equilibration both the contents of the periplasm and proteins localized at the Bayer patches are released to the exterior. A simple centrifugation following this release removes

the majority of bacterial cell-derived contaminants from the fusion protein preparation. Alternatively, in a freeze/thaw procedure the packed cells containing the fusion protein are first resuspended in a buffer containing EDTA and are then frozen. Fusion protein release is subsequently achieved by allowing the frozen cell suspension to thaw. The majority of contaminants can be removed as described above by a centrifugation step. The fusion protein is further purified by well-known conventional methods.

These treatments typically release at least 30% of the fusion proteins without lysing the cell cultures. The success of these procedures in releasing significant amounts of several thioredoxin fusion proteins is surprising, since such techniques are not generally successful with a wide range of proteins. The ability of these fusion proteins to be substantially purified by such treatments, which are significantly simpler and less expensive than the purification methods required by other fusion protein systems, may provide the fusion proteins of the invention with a significant advantage over other systems which are used to produce proteins in E. coli.

The resulting fusion protein is stable and soluble, often with the heterologous peptide or protein retaining its bioactivity. The heterologous peptide or protein may optionally be separated from the thioredoxin-like protein by cleavage, as discussed above.

In the specific and illustrative embodiments of the compositions and methods of this invention, the E. coli thioredoxin (trxA) gene (SEQ ID NO:21) has been cloned and placed in an E. coli expression system. An expression plasmid pALtrxA-781 was constructed. This plasmid containing modified IL-11 fused to the thioredoxin sequence and called pALtrxA/EK/IL11 Δ Pro-581 (SEQ ID NO:13 and SEQ ID NO:14) is described below in Example 1 and in Fig. 1. A modified version of this plasmid containing a different ribosome binding site was employed in the other examples and is specifically described in Example 3. Other

conventional vectors may be employed in this invention. The invention is not limited to the plasmids described in these examples.

5 Plasmid pALtrxA-781 (without the modified IL-11) directs the accumulation of >10% of the total cell protein as thioredoxin in E. coli host strain GI724. Examples 2 through 6 describe the use of this plasmid to form and express thioredoxin fusion proteins with BMP-2 (SEQ ID NO:18), IL6 (SEQ ID NO:20) and MIP-1 α (SEQ ID NO:16), which are polypeptides.

10 As an example of the expression of small peptides inserted into the active-site loop, a derivative of pALtrxA-781 has been constructed in which a 13 amino-acid linker peptide sequence containing a cleavage site for the specific protease enterokinase [Leipnieks and Light, J. Biol. Chem., 254:1077-1083 (1979)] has
15 been fused into the active site loop of thioredoxin. This plasmid (pALtrxA-EK) directs the accumulation of >10% of the total cell protein as the fusion protein. The fusion protein is all soluble, indicating that it has probably adopted a 'native' tertiary structure. It is equally as stable as wild type
20 thioredoxin to prolonged incubations at 80°C, suggesting that the strong tertiary structure of thioredoxin has not been compromised by the insertion into the active site loop. The fusion protein is specifically cleaved by enterokinase, whereas thioredoxin is not, indicating that the peptide inserted into the active site
25 loop is present on the surface of the fusion protein.

As described in more detail in Example 12 below, fusions of small peptides (SEQ ID NO:1 through SEQ ID NO:12) were made into the active site loop of thioredoxin. The inserted peptides were 14 residues long and were of totally random composition to test
30 the ability of the system to deal with hydrophobic, hydrophilic and neutral sequences.

The methods and compositions of this invention permit the production of proteins and peptides useful in research, diagnostic and therapeutic fields. The production of fusion
35 proteins according to this invention has a number of advantages.

As one example, the production of a selected protein by the present invention as a carboxyl-terminal fusion to E. coli thioredoxin (SEQ ID NO:21), or another thioredoxin-like protein, enables avoidance of translation initiation problems often encountered in the production of eukaryotic proteins in E. coli. Additionally the initiator methionine usually remaining on the amino-terminus of the heterologous protein is not present and does not have to be removed when the heterologous protein is made as a carboxyl terminal thioredoxin fusion.

The production of fusion proteins according to this invention reliably improves solubility of desired heterologous proteins and enhances their stability to proteases in the expression system. This invention also enables high level expression of certain desirable therapeutic proteins, e.g., IL-11, which are otherwise produced at low levels in bacterial host cells.

This invention may also confer heat stability to the fusion protein, especially if the heterologous protein itself is heat stable. Because thioredoxin, and presumably all thioredoxin-like proteins are heat stable up to 80°C, the present invention may enable the use of a simple heat treatment as an initial effective purification step for some thioredoxin fusion proteins.

In addition to providing high levels of the selected heterologous proteins or peptides upon cleavage from the fusion protein for therapeutic or other uses, the fusion proteins or fusion peptides of the present invention may themselves be useful as therapeutics provided the thioredoxin-like protein is not antigenic to the animal being treated. Further the thioredoxin-like fusion proteins may provide a vehicle for the delivery of bioactive peptides. As one example, human thioredoxin would not be antigenic in humans, and therefore a fusion protein of the present invention with human thioredoxin may be useful as a vehicle for delivering to humans the biologically active peptide to which it is fused. Because human thioredoxin is an intracellular protein, human thioredoxin fusion proteins may be

produced in an E. coli intracellular expression system. Thus this invention also provides a method for delivering biologically active peptides or proteins to a patient in the form of a fusion protein with an acceptable thioredoxin-like protein.

5 The present invention also provides methods and reagents for screening libraries of random peptides for their potential enzyme inhibitory, hormone/growth factor agonist and hormone/growth factor antagonist activity. Also provided are methods and reagents for the mapping of known protein sequences for regions
10 of potential interest, including receptor binding sites, substrate binding sites, phosphorylation/modification sites, protease cleavage sites, and epitopes.

 Bacterial colonies expressing thioredoxin-like/random peptide fusion proteins may be screened using radiolabelled
15 proteins such as hormones or growth factors as probes. Positives arising from this type of screen would identify mimics of receptor binding sites and may lead to the design of compounds with therapeutic uses. Bacterial colonies expressing thioredoxin-like random peptide fusion proteins may also be
20 screened using antibodies raised against native, active hormones or growth factors. Positives arising from this type of screen could be mimics of surface epitopes present on the original antigen. Where such surface epitopes are responsible for receptor binding, the 'positive' fusion proteins would have
25 biological activity.

 Additionally, the thioredoxin-like fusion proteins or fusion peptides of this invention may also be employed to develop monoclonal and polyclonal antibodies, or recombinant antibodies or chimeric antibodies, generated by known methods for
30 diagnostic, purification or therapeutic use. Studies of thioredoxin-like molecules indicate a possible B cell/T cell growth factor activity [N. Wakasuki et al, cited above], which may enhance immune response. The fusion proteins or peptides of the present invention may be employed as antigens to elicit

desirable antibodies, which themselves may be further manipulated by known techniques into monoclonal or recombinant antibodies.

Alternatively, antibodies elicited to thioredoxin-like sequences may also be useful in the purification of many different thioredoxin fusion proteins. The following examples illustrate embodiments of the present invention, but are not intended to limit the scope of the disclosure.

EXAMPLE 1 - THIOREDOXIN/IL-11 FUSION MOLECULE

A thioredoxin-like fusion molecule of the present invention was prepared using E. coli thioredoxin as the thioredoxin-like sequence and recombinant IL-11 [Paul et al, Proc. Natl. Acad. Sci. U.S.A., 87:7512-7516 (1990); see also, copending United States Patent Applications SN 07/526,474, and SN 07/441,100 and PCT Patent publication WO91/0749, published May 30, 1991 incorporated herein by reference] as the selected heterologous protein. The E. coli thioredoxin (trxA) gene (SEQ ID NO:21) was cloned based on its published sequence and employed to construct various related E. coli expression plasmids using standard DNA manipulation techniques, described extensively by Sambrook, Fritsch and Maniatis, Molecular Cloning. A Laboratory Manual, 2nd edition, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1989).

A first expression plasmid pALtrxA-781 was constructed containing the E. coli trxA gene without fusion to another sequence. This plasmid further contained sequences which are described in detail below for the related IL-11 fusion plasmid. This first plasmid, which directs the accumulation of >10% of the total cell protein as thioredoxin in an E. coli host strain GI724, was further manipulated as described below for the construction of a trxA/IL-11 fusion sequence.

The entire sequence of the related plasmid expression vector, pALtrxA/EK/IL11ΔPro-581 (SEQ ID NO:13 and SEQ ID NO:14), is illustrated in Fig. 1 and contains the following principal features:

Nucleotides 1-2060 contain DNA sequences originating from the plasmid pUC-18 [Norrande et al, Gene, 26: 101-106 (1983)] including sequences containing the gene for β -lactamase which confers resistance to the antibiotic ampicillin in host E. coli strains, and a colE1-derived origin of replication. Nucleotides 2061-2221 contain DNA sequences for the major leftward promoter (pL) of bacteriophage λ [Sanger et al, J. Mol. Biol., 162:729-773 (1982)], including three operator sequences, O_L1, O_L2 and O_L3. The operators are the binding sites for λ CI repressor protein, intracellular levels of which control the amount of transcription initiation from pL. Nucleotides 2222-2241 contain a strong ribosome binding sequence derived from that of gene 10 of bacteriophage T7 [Dunn and Studier J. Mol. Biol., 166:477-535 (1983)].

Nucleotides 2242-2568 contain a DNA sequence encoding the E. coli thioredoxin protein (SEQ ID NO:21) [Lim et al, J. Bacteriol., 163:311-316 (1985)]. There is no translation termination codon at the end of the thioredoxin coding sequence in this plasmid.

Nucleotides 2569-2583 contain DNA sequence encoding the amino acid sequence for a short, hydrophilic, flexible spacer peptide "--GSGSG--". Nucleotides 2584-2598 provide DNA sequence encoding the amino acid sequence for the cleavage recognition site of enterokinase (EC 3.4.4.8), "--DDDDK--" [Maroux et al, J. Biol. Chem., 246:5031-5039 (1971)].

Nucleotides 2599-3132 contain DNA sequence encoding the amino acid sequence of a modified form of mature human IL-11 [Paul et al, Proc. Natl. Acad. Sci. USA, 87:7512-7516 (1990)], deleted for the N-terminal prolyl-residue normally found in the natural protein. The sequence includes a translation termination codon at the 3'-end of the IL-11 sequence.

Nucleotides 3133-3159 provide a "Linker" DNA sequence containing restriction endonuclease sites. Nucleotides 3160-3232 provide a transcription termination sequence based on that of the E. coli aspA gene [Takagi et al, Nucl. Acids Res., 13:2063-2074

(1985)]. Nucleotides 3233-3632 are DNA sequences derived from pUC-18.

As described in Example 2 below, when cultured under the appropriate conditions in a suitable E. coli host strain, this plasmid vector can direct the production of high levels (approximately 10% of the total cellular protein) of a thioredoxin/IL-11 fusion protein. By contrast, when not fused to thioredoxin, IL-11 accumulated to only 0.2% of the total cellular protein when expressed in an analogous host/vector system.

EXAMPLE 2 - EXPRESSION OF A FUSION PROTEIN

A thioredoxin/IL-11 fusion protein was produced according to the following protocol using the plasmid constructed as described in Example 1. pALtrxA/EK/IL11ΔPro-581 (SEQ ID NO:13) was transformed into the E. coli host strain GI724 (F⁻, lacI^q, lacP^{L8}, ampC::λCI⁺) by the procedure of Dagert and Ehrlich, Gene, 6: 23 (1979). The untransformed host strain E. coli GI724 was deposited with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland on January 31, 1991 under ATCC No. 55151 for patent purposes pursuant to applicable laws and regulations. Transformants were selected on 1.5% w/v agar plates containing IMC medium, which is composed of M9 medium [Miller, "Experiments in Molecular Genetics", Cold Spring Harbor Laboratory, New York (1972)] supplemented with 0.5% w/v glucose, 0.2% w/v casamino acids and 100 μg/ml ampicillin.

GI724 contains a copy of the wild-type λCI repressor gene stably integrated into the chromosome at the ampC locus, where it has been placed under the transcriptional control of Salmonella typhimurium trp promoter/operator sequences. In GI724, λCI protein is made only during growth in tryptophan-free media, such as minimal media or a minimal medium supplemented with casamino acids such as IMC, described above. Addition of tryptophan to a culture of GI724 will repress the trp promoter and turn off synthesis of λCI, gradually causing the induction

of transcription from pL promoters if they are present in the cell.

GI724 transformed with pALtrxA/EK/IL11 Δ Pro-581 (SEQ ID NO:13 and SEQ ID NO:14) was grown at 37°C to an A_{550} of 0.5 in IMC
5 medium. Tryptophan was added to a final concentration of 100 μ g/ml and the culture incubated for a further 4 hours. During this time thioredoxin/IL-11 fusion protein accumulated to approximately 10% of the total cell protein.

10 All of the fusion protein was found to be in the soluble cellular fraction, and was purified as follows. Cells were lysed in a french pressure cell at 20,000 psi in 50 mM HEPES pH 8.0, 1 mM phenylmethylsulfonyl fluoride. The lysate was clarified by centrifugation at 15,000 x g for 30 minutes and the supernatant loaded onto a QAE-Toyopearl column. The flow-through fractions
15 were discarded and the fusion protein eluted with 50 mM HEPES pH 8.0, 100 mM NaCl. The eluate was adjusted to 2M NaCl and loaded onto a column of phenyl-Toyopearl. The flow-through fractions were again discarded and the fusion protein eluted with 50 mM HEPES pH 8.0, 0.5 M NaCl.

20 The fusion protein was then dialyzed against 25 mM HEPES pH 8.0 and was >80% pure at this stage. By T1165 bioassay [Paul et al, cited above] the purified thioredoxin-IL11 protein exhibited an activity of 8×10^5 U/mg. This value agrees closely on a molar basis with the activity of 2×10^6 U/mg found for COS cell-derived
25 IL11 in the same assay. One milligram of the fusion protein was cleaved at 37°C for 20 hours with 1000 units of bovine enterokinase [Leipnieks and Light, J. Biol. Chem., 254:1677-1683 (1979)] in 1 ml 10mM Tris-Cl (pH8.0)/10mM CaCl_2 . IL11 could be recovered from the reaction products by passing them over a QAE-Toyopearl column in 25 mM HEPES pH 8.0, where IL11 was found in
30 the flow-through fractions. Uncleaved fusion protein, thioredoxin and enterokinase remained bound on the column.

The IL11 prepared in this manner had a bioactivity in the T1165 assay of 2.5×10^6 U/mg.

EXAMPLE 3 - THIOREDOXIN/MIP-1 α FUSION MOLECULE

Human macrophage inflammatory protein 1 α (MIP-1 α) (SEQ ID NO:16) can be expressed at high levels in E. coli as a thioredoxin fusion protein using an expression vector similar to
5 pALtrxA/EK/IL11 Δ Pro-581 described in Example 1 above but modified in the following manner to replace the ribosome binding site of bacteriophage T7 with that of λ CII. In the plasmid of Example 1, nucleotides 2222 and 2241 were removed by conventional means. Inserted in place of those nucleotides was a sequence of
10 nucleotides formed by nucleotides 35566 to 35472 and 38137 to 38361 from bacteriophage lambda as described in Sanger et al (1982) cited above. This reference is incorporated by reference for the purpose of disclosing this sequence. To express a thioredoxin/MIP-1 α fusion the DNA sequence in the thusly-modified
15 pALtrxA/EK/IL11 Δ Pro-581 encoding human IL11 (nucleotides 2599-3132) is replaced by the 213 nucleotide DNA sequence (SEQ ID NO:15) shown in Fig. 2 encoding full-length, mature human MIP-1 α [Nakao et al, Mol. Cell. Biol., 10:3646-3658 (1990)].

The host strain and expression protocol used for the
20 production of thioredoxin/MIP-1 α fusion protein are as described in Example 1. As was seen with the thioredoxin/IL11 fusion protein, all of the thioredoxin/MIP-1 α fusion protein was found in the soluble cellular fraction, representing up to 20% of the total protein. Cells were lysed as in Example 1 to give a protein
25 concentration in the crude lysate of 10 mg/ml. This lysate was then heated at 80°C for 10 min to precipitate the majority of contaminating E. coli proteins and was clarified by centrifugation at 130,000 x g for 60 minutes. The pellet was discarded and the supernatant loaded onto a Mono Q column. The
30 fusion protein eluted at approximately 0.5 M NaCl from this column and was >80% pure at this stage. After dialysis to remove salt the fusion protein could be cleaved by an enterokinase treatment as described in Example 2 to release MIP-1 α .

EXAMPLE 4 - THIOREDOXIN/BMP2 FUSION MOLECULE

Human Bone Morphogenetic Protein 2 (BMP-2) can be expressed at high levels in E. coli as a thioredoxin fusion protein using the modified expression vector described in Example 3. The DNA sequence encoding human IL-11 in the modified pALtrxA/EK/IL11ΔPro-581 (nucleotides 2599-3132) is replaced by the 345 nucleotide DNA sequence (SEQ ID NO:17) shown in Fig. 3 encoding full-length, mature human BMP-2 [Wozney et al, Science, 242:1528-1534 (1988)].

In this case the thioredoxin/BMP-2 fusion protein appeared in the insoluble cellular fraction when strain GI724 containing the expression vector was grown in medium containing tryptophan at 37°C. However, when the temperature of the growth medium was lowered to 20°C the fusion protein was found in the soluble cellular fraction.

EXAMPLE 5 - THIOREDOXIN/IL-2 FUSION MOLECULE

Murine interleukin 2 (IL-2) is produced at high levels in a soluble form in E. coli as a thioredoxin fusion protein using the modified expression vector described in Example 3. The DNA sequence encoding human IL-11 in the modified pALtrxA/EK/IL11ΔPro-581 vector (nucleotides 2599-3132) is replaced by the DNA sequence encoding murine IL-2, Genbank Accession No. K02292, nucleotides 109 to 555. The thioredoxin/IL-2 fusion gene is expressed under the conditions described for thioredoxin/IL-11 in Example 2. The culture growth temperature used in this case is 15°C. Under these conditions the majority of the thioredoxin/IL-2 fusion protein accumulates in the soluble cellular fraction. The fusion protein can be cleaved using the enterokinase treatment described in Example 2.

EXAMPLE 6 - THIOREDOXIN/IL-3 FUSION MOLECULE

Human interleukin 3 (IL-3) is produced at high levels in a soluble form in E. coli as a thioredoxin fusion protein using the modified expression vector described in Example 3. The DNA

sequence encoding human IL-11 in the modified pALtrxA/EK/IL11ΔPro-581 vector (nucleotides 2599-3132 is replaced by the DNA sequence encoding human IL-3, Genbank Accession No. M14743, nucleotides 67 to 465. The thioredoxin/IL-3 fusion gene
5 is expressed under the conditions described for thioredoxin/IL-11 in Example 2. The culture growth temperature used in this case is 15°C. Under these conditions the majority of the thioredoxin/IL-3 fusion protein accumulates in the soluble cellular fraction. The fusion protein can be cleaved using the
10 enterokinase treatment described in Example 2.

EXAMPLE 7 - THIOREDOXIN/IL-4 FUSION MOLECULE

Murine interleukin 4 (IL-4) is produced at high levels in a soluble form in E. coli as a thioredoxin fusion using the
15 modified expression vector described in Example 3. The DNA sequence encoding human IL-11 in the modified pALtrxA/EK/IL11ΔPro-581 vector (nucleotides 2599-3122 is replaced by the DNA sequence encoding murine IL-4, Genbank Accession No. M13238, nucleotides 122 to 477. The thioredoxin/IL-4 fusion gene
20 is expressed under the conditions described for thioredoxin/IL-11 in Example 2. The culture growth temperature used in this case is 15°C. Under these conditions the majority of the thioredoxin/IL-4 fusion protein accumulates in the soluble cellular fraction. The fusion protein can be cleaved using the
25 enterokinase treatment described in Example 2.

EXAMPLE 8 - THIOREDOXIN/IL-5 FUSION MOLECULE

Murine interleukin 5 (IL-5) is produced at high levels in a soluble form in E. coli as a thioredoxin fusion protein using
30 the modified expression vector described in Example 3. The DNA sequence encoding human IL-11 in the modified pALtrxA/EK/IL11ΔPro-581 vector (nucleotides 2599-3132 is replaced by the DNA sequence encoding murine IL-5, Genbank Accession No. X04601, nucleotides 107 to 443. The thioredoxin/murine IL-5
35

fusion gene is expressed under the conditions described for thioredoxin/IL-11 in Example 2. The culture growth temperature used in this case is 15°C. Under these conditions the majority of the thioredoxin/murine IL-5 fusion protein accumulates in the soluble cellular fraction. The fusion protein can be cleaved using the enterokinase treatment described in Example 2.

EXAMPLE 9 - THIOREDOXIN/LIF FUSION MOLECULE

Murine LIF is produced at high levels in a soluble form in E. coli as a thioredoxin fusion protein using the modified expression vector described in Example 3. The DNA sequence encoding human IL-11 in the modified pALtrxA/EK/IL11ΔPro-581 vector (nucleotides 2599-3132 is replaced by the DNA sequence encoding murine LIF, Genbank Accession No. X12810, nucleotides 123 to 734. The thioredoxin/LIF fusion gene is expressed under the conditions described for thioredoxin/IL-11 in Example 2. The culture growth temperature used in this case is 25°C. Under these conditions the majority of the thioredoxin/LIF fusion protein accumulates in the soluble cellular fraction. The fusion protein can be cleaved using the enterokinase treatment described in Example 2.

EXAMPLE 10 - THIOREDOXIN/STEEL FACTOR FUSION MOLECULE

Murine Steel Factor is produced at high levels in a soluble form in E. coli as a thioredoxin fusion protein using the modified expression vector described in Example 3. The DNA sequence encoding human IL-11 in the modified pALtrxA/EK/IL11ΔPro-581 vector (nucleotides 2599-3132 is replaced by the DNA sequence encoding murine Steel Factor, Genbank Accession No. M59915, nucleotides 91 to 583. The thioredoxin/Steel Factor fusion gene is expressed under the conditions described for thioredoxin/IL-11 in Example 2. The culture growth temperature used in this case is 37°C. Under these conditions the majority of the thioredoxin/Steel Factor fusion protein accumulates in the

soluble cellular fraction. The fusion protein can be cleaved using the enterokinase treatment described in Example 2.

EXAMPLE 11 - THIOREDOXIN/MIF FUSION MOLECULE

5 Human Macrophage Inhibitory Factor (MIF) is produced at high levels in a soluble form E. coli as a thioredoxin fusion protein using the modified expression vector described in Example 3. The DNA sequence encoding human IL-11 in the modified pALtrxA/EK/IL11ΔPro-581 vector (nucleotides 2599-3132) is
10 replaced by the DNA sequence encoding human MIF, Genbank Accession No. M25639, nucleotides 51 to 397. The thioredoxin/MIF fusion gene is expressed under the conditions described for the thioredoxin/IL-11 in Example 2. The culture growth temperature used in this case is 37°C. Under these conditions the majority
15 of the thioredoxin/MIF fusion protein accumulates in the soluble cellular fraction. The fusion protein can be cleaved using the enterokinase treatment described in Example 2.

EXAMPLE 12 - THIOREDOXIN/SMALL PEPTIDE FUSION MOLECULES

20 Native E. coli thioredoxin can be expressed at high levels in E. coli using strain GI724 containing the same plasmid expression vector described in Example 3 deleted for nucleotides 2569-3129, and employing the growth and induction protocol outlined in Example 1. Under these conditions thioredoxin
25 accumulated to approximately 10% of the total protein, all of it in the soluble cellular fraction.

Fig. 4 illustrates insertion of 13 amino acid residues encoding an enterokinase cleavage site into the active site loop of thioredoxin, between residues G₃₄ and P₃₅ of the thioredoxin
30 protein sequence. The fusion protein containing this internal enterokinase site was expressed at levels equivalent to native thioredoxin, and was cleaved with an enterokinase treatment as outlined in Example 1 above. The fusion protein was found to be as stable as native thioredoxin to heat treatments, being

resistant to a 10 minute incubation at 80°C as described in Example 4.

Below are listed twelve additional peptide insertions which were also made into the active site loop of thioredoxin between G₃₄ and P₃₅. The sequences are each 14 amino acid residues in length and are random in composition. Each of the thioredoxin fusion proteins containing these random insertions were made at levels comparable to native thioredoxin. All of them were found in the soluble cellular fraction. These peptides include the following sequences:

Pro-Leu-Gln-Arg-Ile-Pro-Pro-Gln-Ala-Leu-Arg-Val-Glu-Gly (SEQ ID NO:1),

Pro-Arg-Asp-Cys-Val-Gln-Arg-Gly-Lys-Ser-Leu-Ser-Leu-Gly (SEQ ID NO:2),

Pro-Met-Arg-His-Asp-Val-Arg-Cys-Val-Leu-His-Gly-Thr-Gly (SEQ ID NO:3),

Pro-Gly-Val-Arg-Leu-Pro-Ile-Cys-Tyr-Asp-Asp-Ile-Arg-Gly (SEQ ID NO:4),

Pro-Lys-Phe-Ser-Asp-Gly-Ala-Gln-Gly-Leu-Gly-Ala-Val-Gly (SEQ ID NO:5),

Pro-Pro-Ser-Leu-Val-Gln-Asp-Asp-Ser-Phe-Glu-Asp-Arg-Gly (SEQ ID NO:6),

Pro-Trp-Ile-Asn-Gly-Ala-Thr-Pro-Val-Lys-Ser-Ser-Ser-Gly (SEQ ID NO:7),

Pro-Ala-His-Arg-Phe-Arg-Gly-Gly-Ser-Pro-Ala-Ile-Phe-Gly (SEQ ID NO:8),

Pro-Ile-Met-Gly-Ala-Ser-His-Gly-Glu-Arg-Gly-Pro-Glu-Gly (SEQ ID NO:9),

Pro-Asp-Ser-Leu-Arg-Arg-Arg-Glu-Gly-Phe-Gly-Leu-Leu-Gly (SEQ ID NO:10),

Pro-Ser-Glu-Tyr-Pro-Gly-Leu-Ala-Thr-Gly-His-His-Val-Gly (SEQ ID NO: 11),

and Pro-Leu-Gly-Val-Leu-Gly-Ser-Ile-Trp-Leu-Glu-Arg-Gln-Gly (SEQ ID NO:12).

The inserted sequences contained examples that were both hydrophobic and hydrophilic, and examples that contained cysteine residues. It appears that the active-site loop of thioredoxin can tolerate a wide variety of peptide insertions resulting in soluble fusion proteins. Standard procedures can be used to purify these loop "inserts".

EXAMPLE 13 - HUMAN INTERLEUKIN-6

Human interleukin-6 (IL-6) is expressed at high levels in E. coli as a thioredoxin fusion protein using an expression vector similar to modified pALtrxA/EK/IL11ΔPro-581 described in Example 3 above. To express a thioredoxin-IL6 fusion the DNA sequence in modified pALtrxA/EK/IL11ΔPro-581 encoding human IL-11 (nucleotides 2599-3132) is replaced by the 561 nucleotide DNA sequence (SEQ ID NO:19) shown in Figure 6 encoding full-length, mature human IL-6 [Hirano et al, Nature, 324:73-76 (1986)]. The host strain and expression protocol used for the production of thioredoxin/IL-6 fusion protein are as described in Example 1.

When the fusion protein was synthesized at 37°C, approximately 50% of it was found in the "inclusion body" or insoluble fraction. However all of the thioredoxin-IL6 fusion protein, representing up to 10% of the total cellular protein, was found in the soluble fraction when the temperature of synthesis was lowered to 25°C.

EXAMPLE 14 - HUMAN MACROPHAGE COLONY STIMULATING FACTOR

Human Macrophage Colony Stimulating Factor (M-CSF) can be expressed at high levels in E. coli as a thioredoxin fusion protein using the modified expression vector similar to pALtrxA/EK/IL11ΔPro-581 described in Example 3 above.

The DNA sequence encoding human IL-11 in modified pALtrxA/EK/IL11ΔPro-581 (nucleotides 2599-3135) is replaced by the 669 nucleotide DNA sequence shown in Fig. 7 encoding the first 223 amino acids of mature human M-CSFβ [G. G. Wong et al, Science, 235:1504-1508 (1987)]. The host strain and expression

protocol used for the production of thioredoxin/M-CSF fusion protein was as described in Example 2 above.

As was seen with the thioredoxin/IL-11 fusion protein, all of the thioredoxin/M-CSF fusion protein was found in the soluble cellular fraction, representing up to 10% of the total protein.

EXAMPLE 15 - RELEASE OF FUSION PROTEIN VIA OSMOTIC SHOCK

To determine whether or not the fusions of heterologous proteins to thioredoxin according to this invention enable targeting to the host cell's adhesion sites and permit the release of the fusion proteins from the cell, the cells were exposed to simple osmotic shock and freeze/thaw procedures.

Cells overproducing wild-type E. coli thioredoxin, human thioredoxin, the E. coli thioredoxin-MIP1 α fusion or the E. coli thioredoxin-IL11 fusion were used in the following procedures.

For an osmotic shock treatment, cells were resuspended at 2 A₅₅₀/ml in 20 mM Tris-Cl pH 8.0/2.5 mM EDTA/20% w/v sucrose and kept cold on ice for 10 minutes. The cells were then pelleted by centrifugation (12,000 xg, 30 seconds) and gently resuspended in the same buffer as above but with sucrose omitted. After an additional 10 minute period on ice, to allow for the osmotic release of proteins, cells were re-pelleted by centrifugation (12,000 xg, 2 minutes) and the supernatant ("shockate") examined for its protein content. Wild-type E. coli thioredoxin and human thioredoxin were quantitatively released, giving "shockate" preparations which were >80% pure thioredoxin. More significantly >80% of the thioredoxin-MIP1 α and >50% of the thioredoxin-IL11 fusion proteins were released by this osmotic treatment.

A simple freeze/thaw procedure produced similar results, releasing thioredoxin fusion proteins selectively, while leaving most of the other cellular proteins inside the cell. A typical freeze/thaw procedure entails resuspending cells at 2 A₅₅₀/ml in 20 mM Tris-Cl pH 8.0/2.5 mM EDTA and quickly freezing the

suspension in dry ice or liquid nitrogen. The frozen suspension is then allowed to slowly thaw before spinning out the cells (12,000 xg, 2 minutes) and examining the supernatant for protein.

Although the resultant "shockate" may require additional
5 purification, the initial "shockate" is characterized by the absence of nucleic acid contaminants. Thus, compared to an initial lysate, the purity of the "shockate" is significantly better, and does not require the difficult removal of DNA from bacterial lysates. Fewer additional steps should be required for
10 total purity of the "shockate".

Numerous modifications and variations of the present invention are included in the above-identified specification and are expected to be obvious to one of skill in the art. Such modifications and alterations to the compositions and processes
15 of the present invention are believed to be encompassed in the scope of the claims appended hereto.

WHAT IS CLAIMED IS:

1. A DNA sequence comprising DNA encoding one or more thioredoxin-like proteins fused to a DNA sequence encoding a selected, desired peptide or protein, said sequence capable of encoding a fusion protein.

2. The sequence according to claim 1 wherein said thioredoxin-like DNA sequence is selected from the group consisting of the E. coli thioredoxin [sequence SEQ ID NO:21], human thioredoxin, glutaredoxin, and the thioredoxin-like domains of protein disulfide isomerase, form-1 phosphoinositide-specific phospholipase C and ERp72.

3. The sequence according to claim 1 wherein said selected peptide or protein is selected from the group consisting of IL-11, IL-6 [SEQ ID NO:2]0, Macrophage Inhibitory Protein 1 α [SEQ ID NO:16], Bone Morphogenic Protein 2 [SEQ ID NO:18], IL-2, IL-3, IL-4, IL-5, MIF, LIF, Steel Factor and randomly generated peptide sequences [SEQ ID NO:1 through SEQ ID NO:12].

4. The sequence according to claim 1 further comprising a linker peptide between the thioredoxin-like sequence and said selected peptide or protein, said linker providing a selected cleavage site and preventing steric hindrance between the thioredoxin-like molecule and said selected peptide or protein.

5. A plasmid DNA molecule comprising DNA encoding one or more thioredoxin-like proteins fused to the DNA sequence encoding a selected, desired peptide or protein, said fusion sequence under the control of an expression control sequence comprising a promoter functional in E. coli, a ribosome binding site, an origin of replication and an optional selectable marker, said control sequence capable of directing the expression of a fusion protein in a selected host cell.

6. A host cell transformed with, or having integrated into the genome thereof, a DNA molecule comprising a DNA sequence encoding at least one thioredoxin-like protein fused to a DNA sequence encoding a selected, desired peptide or protein, said fusion sequence under the control of an expression control sequence capable of directing the expression of a cytoplasmic fusion protein.

7. A fusion protein comprising a thioredoxin-like protein fused in frame to a selected, desired peptide or protein.

8. A method for increasing the expression of a selected recombinant protein comprising culturing under suitable conditions a host cell transformed with, or having integrated into the genome thereof, a DNA molecule comprising a DNA sequence encoding at least one thioredoxin-like protein fused to a DNA sequence encoding said heterologous protein, said fusion sequence under the control of an expression control sequence capable of directing the expression of a fusion protein; recovering said fusion protein from said culture; and optionally cleaving said protein from fusion with said thioredoxin-like protein.

9. The method according to claim 8 wherein said recovering step comprises treating said transformed and cultured cells by osmotic shock to release said fusion protein from the cell.

10. The method according to claim 8 wherein said recovering step comprises treating said transformed and cultured cells by freezing and thawing to release said fusion protein from the cell.

FIG. 1/7

pALtrxA/EK/IL11ΔPro-581

SEQ ID NO:13 and SEQ ID NO:14

GACGAAAGGG	CCTCGTGATA	CGCCTATTTT	TATAGGTAA	40
TGTCATGATA	ATAATGGTTT	CTTAGACGTC	AGGTGGCACT	80
TTTCGGGGAA	ATGTGCGCGG	AACCCCTATT	TGTTTATTTT	120
TCTAAATACA	TTCAAATATG	TATCCGCTCA	TGAGACAATA	160
ACCCTGATAA	ATGCTTCAAT	AATATTGAAA	AAGGAAGAGT	200
ATGAGTATTC	AACATTTCCG	TGTCGCCCTT	ATTCCCTTTT	240
TTGCGGCATT	TTGCCTTCCT	GTTTTTGCTC	ACCCAGAAAC	280
GCTGGTGAAA	GTAAAAGATG	CTGAAGATCA	GTTGGGTGCA	320
CGAGTGGGTT	ACATCGAACT	GGATCTCAAC	AGCGGTAAGA	360
TCCTTGAGAG	TTTTCGCCCC	GAAGAACGTT	TTCCAATGAT	400
GAGCACTTTT	AAAGTTCTGC	TATGTGGCGC	GGTATTATCC	440
CGTATTGACG	CCGGGCAAGA	GCAACTCGGT	CGCCGCATAC	480
ACTATTCTCA	GAATGACTTG	GTTGAGTACT	CACCAGTCAC	520
AGAAAAGCAT	CTTACGGATG	GCATGACAGT	AAGAGAATTA	560
TGCAGTGCTG	CCATAACCAT	GAGTGATAAC	ACTGCGGCCA	600
ACTTACTTCT	GACAACGATC	GGAGGACCGA	AGGAGCTAAC	640
CGCTTTTTTG	CACAACATGG	GGGATCATGT	AACTCGCCTT	680
GATCGTTGGG	AACCGGAGCT	GAATGAAGCC	ATACCAAACG	720
ACGAGCGTGA	CACCACGATG	CCTGTAGCAA	TGGCAACAAC	760
GTTGCGCAAA	CTATTAAGTG	GCGAACTACT	TACTCTAGCT	800
TCCCGGCAAC	AATTAATAGA	CTGGATGGAG	GCGGATAAAG	840
TTGCAGGACC	ACTTCTGCGC	TCGGCCCTTC	CGGCTGGCTG	880
GTTTATTGCT	GATAAATCTG	GAGCCGGTGA	GCGTGGGTCT	920
CGCGGTATCA	TTGCAGCACT	GGGGCCAGAT	GGTAAGCCCT	960
CCCGTATCGT	AGTTATCTAC	ACGACGGGGA	GTCAGGCAAC	1000
TATGGATGAA	CGAAATAGAC	AGATCGCTGA	GATAGGTGCC	1040
TCACTGATTA	AGCATTGGTA	ACTGTCAGAC	CAAGTTTACT	1080
CATATATACT	TTAGATTGAT	TTAAAACTTC	ATTTTAAATT	1120
TAAAAGGATC	TAGGTGAAGA	TCCTTTTGA	TAATCTCATG	1160
ACCAAATCC	CTTAACGTGA	GTTTTCGTTC	CACTGAGCGT	1200
CAGACCCCGT	AGAAAAGATC	AAAGGATCTT	CTTGAGATCC	1240
TTTTTTTCTG	CGCGTAATCT	GCTGCTTGCA	AACAAAAAAA	1280
CCACCGCTAC	CAGCGGTGGT	TTGTTTGCCG	GATCAAGAGC	1320
TACCAACTCT	TTTTCCGAAG	GTAAGTGGCT	TCAGCAGAGC	1360

FIG 1A/7

GCAGATACCA	AATACTGTCC	TTCTAGTGTA	GCCGTAGTTA	1400
GGCCACCACT	TCAAGAACTC	TGTAGCACCG	CCTACATACC	1440
TCGCTCTGCT	AATCCTGTTA	CCAGTGGCTG	CTGCCAGTGG	1480
CGATAAGTCG	TGTCTTACCG	GGTTGGACTC	AAGACGATAG	1520
TTACCGGATA	AGGCGCAGCG	GTCGGGCTGA	ACGGGGGGTT	1560
CGTGACACACA	GCCCAGCTTG	GAGCGAACGA	CCTACACCGA	1600
ACTGAGATAC	CTACAGCGTG	AGCATTGAGA	AAGCGCCACG	1640
CTTCCCGAAG	GGAGAAAGGC	GGACAGGTAT	CCGGTAAGCG	1680
GCAGGGTCGG	AACAGGAGAG	CGCACGAGGG	AGCTTCCAGG	1720
GGGAAACGCC	TGGTATCTTT	ATAGTCCTGT	CGGGTTTCGC	1760
CACCTCTGAC	TTGAGCGTCG	ATTTTTGTGA	TGCTCGTCAG	1800
GGGGGCGGAG	CCTATGGAAA	AACGCCAGCA	ACGCGGCCTT	1840
TTTACGGTTC	CTGGCCTTTT	GCTGGCCTTT	TGCTCACATG	1880
TTCTTTCCTG	CGTTATCCCC	TGATTCTGTG	GATAACCGTA	1920
TTACCGCCTT	TGAGTGAGCT	GATACCGCTC	GCCGCAGCCG	1960
AACGACCGAG	CGCAGCGAGT	CAGTGAGCGA	GGAAGCGGAA	2000
GAGCGCCCAA	TACGCAAACC	GCCTCTCCCC	GCGCGTTGGC	2040
CGATTTCATTA	ATGCAGAATT	GATCTCTCAC	CTACCAAACA	2080
ATGCCCCCCT	GCAAAAAATA	AATTCATATA	AAAAACATAC	2120
AGATAACCAT	CTGCGGTGAT	AAATTATCTC	TGGCGGTGTT	2160
GACATAAATA	CCACTGGCGG	TGATACTGAG	CACATCAGCA	2200
GGACGCACTG	ACCACCATGA	ATTCAAGAAG	GAGATATACA	2240
T ATG AGC GAT AAA ATT ATT CAC CTG ACT GAC GAC				2274
Met Ser Asp Lys Ile Ile His Leu Thr Asp Asp				
1	5	10		
AGT TTT GAC ACG GAT GTA CTC AAA GCG GAC GGG				2307
Ser Phe Asp Thr Asp Val Leu Lys Ala Asp Gly				
	15	20		
GCG ATC CTC GTC GAT TTC TGG GCA GAG TGG TGC				2340
Ala Ile Leu Val Asp Phe Trp Ala Glu Trp Cys				
	25	30		
GGT CCG TGC AAA ATG ATC GCC CCG ATT CTG GAT				2373
Gly Pro Cys Lys Met Ile Ala Pro Ile Leu Asp				
	35	40		
GAA ATC GCT GAC GAA TAT CAG GGC AAA CTG ACC				2406
Glu Ile Ala Asp Glu Tyr Gln Gly Lys Leu Thr				
45	50	55		

FIG. 1B/7

GTT	GCA	AAA	CTG	AAC	ATC	GAT	CAA	AAC	CCT	GGC	2439
Val	Ala	Lys	Leu	Asn	Ile	Asp	Gln	Asn	Pro	Gly	
				60						65	
ACT	GCG	CCG	AAA	TAT	GGC	ATC	CGT	GGT	ATC	CCG	2472
Thr	Ala	Pro	Lys	Tyr	Gly	Ile	Arg	Gly	Ile	Pro	
			70							75	
ACT	CTG	CTG	CTG	TTC	AAA	AAC	GGT	GAA	GTG	GCG	2505
Thr	Leu	Leu	Leu	Phe	Lys	Asn	Gly	Glu	Val	Ala	
			80							85	
GCA	ACC	AAA	GTG	GGT	GCA	CTG	TCT	AAA	GGT	CAG	2538
Ala	Thr	Lys	Val	Gly	Ala	Leu	Ser	Lys	Gly	Gln	
			90							95	
TTG	AAA	GAG	TTC	CTC	GAC	GCT	AAC	CTG	GCC	GGT	2571
Leu	Lys	Glu	Phe	Leu	Asp	Ala	Asn	Leu	Ala	Gly	
100					105					110	
TCT	GGT	TCT	GGT	GAT	GAC	GAT	GAC	AAA	GGT	CCA	2604
Ser	Gly	Ser	Gly	Asp	Asp	Asp	Asp	Lys	Gly	Pro	
				115						120	
CCA	CCA	GGT	CCA	CCT	CGA	GTT	TCC	CCA	GAC	CCT	2637
Pro	Pro	Gly	Pro	Pro	Arg	Val	Ser	Pro	Asp	Pro	
			125							130	
CGG	GCC	GAG	CTG	GAC	AGC	ACC	GTG	CTC	CTG	ACC	2670
Arg	Ala	Glu	Leu	Asp	Ser	Thr	Val	Leu	Leu	Thr	
			135							140	
CGC	TCT	CTC	CTG	GCG	GAC	ACG	CGG	CAG	CTG	GCT	2703
Arg	Ser	Leu	Leu	Ala	Asp	Thr	Arg	Gln	Leu	Ala	
			145							150	
GCA	CAG	CTG	AGG	GAC	AAA	TTC	CCA	GCT	GAC	GGG	2736
Ala	Gln	Leu	Arg	Asp	Lys	Phe	Pro	Ala	Asp	Gly	
155					160					165	
GAC	CAC	AAC	CTG	GAT	TCC	CTG	CCC	ACC	CTG	GCC	2769
Asp	His	Asn	Leu	Asp	Ser	Leu	Pro	Thr	Leu	Ala	
				170						175	
ATG	AGT	GCG	GGG	GCA	CTG	GGA	GCT	CTA	CAG	CTC	2802
Met	Ser	Ala	Gly	Ala	Leu	Gly	Ala	Leu	Gln	Leu	
			180							185	
CCA	GGT	GTG	CTG	ACA	AGG	CTG	CGA	GCG	GAC	CTA	2835
Pro	Gly	Val	Leu	Thr	Arg	Leu	Arg	Ala	Asp	Leu	
			190							195	

FIG. 1C/7

CTG TCC TAC CTG CGG CAC GTG CAG TGG CTG CGC Leu Ser Tyr Leu Arg His Val Gln Trp Leu Arg 200 205	2868	
CGG GCA GGT GGC TCT TCC CTG AAG ACC CTG GAG Arg Ala Gly Gly Ser Ser Leu Lys Thr Leu Glu 210 215 220	2901	
CCC GAG CTG GGC ACC CTG CAG GCC CGA CTG GAC Pro Glu Leu Gly Thr Leu Gln Ala Arg Leu Asp 225 230	2934	
CGG CTG CTG CGC CGG CTG CAG CTC CTG ATG TCC Arg Leu Leu Arg Arg Leu Gln Leu Leu Met Ser 235 240	2967	
CGC CTG GCC CTG CCC CAG CCA CCC CCG GAC CCG Leu Ala Leu Pro Gln Pro Pro Pro Asp Pro 245 250	3000	Arg
CCG GCG CCC CCG CTG GCG CCC CCC TCC TCA GCC Pro Ala Pro Pro Leu Ala Pro Pro Ser Ser Ala 255 260	3033	
TGG GGG GGC ATC AGG GCC GCC CAC GCC ATC CTG Trp Gly Gly Ile Arg Ala Ala His Ala Ile Leu 265 270 275	3066	
GGG GGG CTG CAC CTG ACA CTT GAC TGG GCC GTG Gly Gly Leu His Leu Thr Leu Asp Trp Ala Val 280 285	3099	
AGG GGA CTG CTG CTG CTG AAG ACT CGG CTG TGA Arg Gly Leu Leu Leu Leu Lys Thr Arg Leu 290 295	3132	
AAGCTTATCG ATACCGTCGA CCTGCAGTAA TCGTACAGGG	3172	
TAGTACAAAT AAAAAAGGCA CGTCAGATGA CGTGCCTTTT	3212	
TTCTTG TGAG CAGTAAGCTT GGC ACTGGCC GTCGTTTTAC	3252	
AACGTCGTGA CTGGGAAAAC CCTGGCGTTA CCCAACTTAA	3292	
TCGCCTTGCA GCACATCCCC CTTTCGCCAG CTGGCGTAAT	3332	
AGCGAAGAGG CCCGCACCGA TCGCCCTTCC CAACAGTTGC	3372	
GCAGCCTGAA TGGCGAATGG CGCCTGATGC GGTATTTTCT	3412	
CCTTACGCAT CTGTGCGGTA TTTCACACCG CATATATGGT	3452	

FIG. 1D/7

GCACTCTCAG TACAATCTGC TCTGATGCCG CATAGTTAAG	3492
CCAGCCCCGA CACCCGCCAA CACCCGCTGA CGCGCCCTGA	3532
CGGGCTTGTC TGCTCCCGGC ATCCGCTTAC AGACAAGCTG	3572
TGACCGTCTC CGGGAGCTGC ATGTGTCAGA GGTTTTCACC	3612
GTCATCACCG AAACGCGCGA	3632

FIG. 2/7

MIP-1 α

SEQ ID NO:15 and SEQ ID NO:16

GCA	CCA	CTT	GCT	GCT	GAC	ACG	CCG	ACC	GCC	TGC	TGC	36
Ala	Pro	Leu	Ala	Ala	Asp	Thr	Pro	Thr	Ala	Cys	Cys	
1				5					10			
TTC	AGC	TAC	ACC	TCC	CGA	CAG	ATT	CCA	CAG	AAT	TTC	72
Phe	Ser	Tyr	Thr	Ser	Arg	Gln	Ile	Pro	Gln	Asn	Phe	
		15					20					
ATA	GCT	GAC	TAC	TTT	GAG	ACG	AGC	AGC	CAG	TGC	TCC	109
Ile	Ala	Asp	Tyr	Phe	Glu	Thr	Ser	Ser	Gln	Cys	Ser	
25					30					35		
AAG	CCC	AGT	GTC	ATC	TTC	CTA	ACC	AAG	AGA	GGC	CGG	145
Lys	Pro	Ser	Val	Ile	Phe	Leu	Thr	Lys	Arg	Gly	Arg	
			40					45				
CAG	GTC	TGT	GCT	GAC	CCC	AGT	GAG	GAG	TGG	GTC	CAG	181
Gln	Val	Cys	Ala	Asp	Pro	Ser	Glu	Glu	Trp	Val	Gln	
	50					55					60	
AAA	TAC	GTC	AGT	GAC	CTG	GAG	CTG	AGT	GCC	TAA		214
Lys	Thr	Val	Ser	Asp	Leu	Glu	Leu	Ser	Ala			
				65					70			

FIG. 3/7


BMP-2

SEQ ID NO:17 and SEQ ID NO:18

CAA Gln 1	GCT Ala	AAA Lys	CAT His	AAA Lys 5	CAA Gln	CGT Arg	AAA Lys	CGT Arg	CTG Leu 10	AAA Lys	TCT Ser	36
AGC Ser	TGT Cys	AAG Lys 15	AGA Arg	CAC His	CCT Pro	TTG Leu	TAC Tyr 20	GTG Val	GAC Asp	TTC Phe	AGT Ser	72
GAC Asp 25	GTG Val	GGG Gly	TGG Trp	AAT Asn	GAC Asp 30	TGG Trp	ATT Ile	GTG Val	GCT Ala	CCC Pro 35	CCG Pro	109
GGG Gly	TAT Tyr	CAC His	GCC Ala 40	TTT Phe	TAC Tyr	TGC Cys	CAC His	GGA Gly 45	GAA Glu	TGC Cys	CCT Pro	145
TTT Phe 50	CCT Pro	CTG Leu	GCT Ala	GAT Asp	CAT His	CTG Leu 55	AAC Asn	TCC Ser	ACT Thr	AAT Asn 60	CAT His	181
GCC Ala	ATT Ile	GTT Val	CAG Gln	ACG Thr 65	TTG Leu	GTC Val	AAC Asn	TCT Ser	GTT Val 70	AAC Asn	TCT Ser	217
AAG Lys	ATT Ile	CCT Pro 75	AAG Lys	GCA Ala	TGC Cys	TGT Cys	GTC Val 80	CCG Pro	ACA Thr	GAA Glu	CTC Leu	253
AGT Ser 85	GCT Ala	ATC Ile	TCG Ser	ATG Met	CTG Leu 90	TAC Tyr	CTT Leu	GAC Asp	GAG Glu	AAT Asn 95	GAA Glu	289
AAG Lys	GTT Val	GTA Val	TTA Leu 100	AAG Lys	AAC Asn	TAT Tyr	CAG Gln	GAC Asp 105	ATG Met	GTT Val	GTG Val	325
GAG Glu	GGT Gly 110	TGT Cys	GGG Gly	TGT Cys	CGC Arg	TAG						346

FIG. 4/7

INSERTION OF AN ENTEROKINASE SITE INTO
THE ACTIVE-SITE LOOP OF E.COLI THIOREDOXIN (trxA)



Enterokinase site
(13 residues)



RANDOM PEPTIDE INSERTIONS INTO THE ACTIVE-SITE
LOOP OF E.COLI THIOREDOXIN (trxA)

```

                                RsrII
                                |
trxA active site loop      ....GAGTGGTGCGGTCCGTGCAAAATG....
                             -----
                             ....CTCACCACGCCAGGCACGTTTTAC....

                             ....E W C G P C K M ....
                             31                               38


RsrII cut                  ....GAGTGGTGCG                      GTCCGTGCAAAATG....
                             -----                             -----
                             ....CTCACCACGCCAG                      GCACGTTTTAC....

                             ....E W C G                      P C K M ....
                             31                               38


oligos                    (AvaII)                      AvaII
5'                          |                          | 3'
GACTGACTGGTCCG... (N36) ...GGTCCTCAGTCAGTCAG
-----
                                CCAGGAGTCAGTCAGTC
                                3'                          5'


random duplex              GTCCG... (N36) ...G
                             -----
                             GC... (N36) ...CCAG

insertion into trxA active site loop

      ....GAGTGGTGCGGTCCG... (N36) ...GGTCCGTGCAAAATG....
      -----
      ....CTCACCACGCCAGGC... (N36) ...CCAGGCACGTTTTAC....

      ....E W C G P . . (X12) . . G P C K M ....
      31                               38

```


FIG. 6/7

IL6

SEQ ID NO:19 and SEQ ID NO:20

					5					10							
ATG	GCT	CCA	GTA	CCT	CCA	GGT	GAA	GAT	TCT	AAA	GAT	GTA					39
Met	Ala	Pro	Val	Pro	Pro	Gly	Glu	Asp	Ser	Lys	Asp	Val					
		15				20						25					
GCC	GCC	CCA	CAC	AGA	CAG	CCA	CTC	ACC	TCT	TCA	GAA	CGA					78
Ala	Ala	Pro	His	Arg	Gln	Pro	Leu	Thr	Ser	Ser	Glu	Arg					
				30					35								
ATT	GAC	AAA	CAA	ATT	CGG	TAC	ATC	CTC	GAC	GGC	ATC	TCA					117
Ile	Asp	Lys	Gln	Ile	Arg	Tyr	Ile	Leu	Asp	Gly	Ile	Ser					
		40				45					50						
GCC	CTG	AGA	AAG	GAG	ACA	TGT	AAC	AAG	AGT	AAC	ATG	TGT					156
Ala	Leu	Arg	Lys	Glu	Thr	Cys	Asn	Lys	Ser	Asn	Met	Cys					
			55				60										
GAA	AGC	AGC	AAA	GAG	GCA	CTG	GCA	GAA	AAC	AAC	CTG	AAC					195
Glu	Ser	Ser	Lys	Glu	Ala	Leu	Ala	Glu	Asn	Asn	Leu	Asn					
	65				70				75								
CTT	CCA	AAG	ATG	GCT	GAA	AAA	GAT	GGA	TGC	TTC	CAA	TCT					234
Leu	Pro	Lys	Met	Ala	Glu	Lys	Asp	Gly	Cys	Phe	Gln	Ser					
		80				85				90							
GGA	TTC	AAT	GAG	GAG	ACT	TGC	CTG	GTG	AAA	ATC	ATC	ACT					273
Gly	Phe	Asn	Glu	Glu	Thr	Cys	Leu	Val	Lys	Ile	Ile	Thr					
			95				100										
GGT	CTT	TTG	GAG	TTT	GAG	GTA	TAC	CTA	GAG	TAC	CTC	CAG					312
Gly	Leu	Leu	Glu	Phe	Glu	Val	Tyr	Leu	Glu	Thr	Leu	Gln					
		105				110					115						
AAC	AGA	TTT	GAG	AGT	AGT	GAG	GAA	CAA	GCC	AGA	GCT	GTG					351
Asn	Arg	Phe	Glu	Ser	Ser	Glu	Glu	Gln	Ala	Arg	Ala	Val					

FIG. 7 of 7
(SEQ ID NO: 23)
(SEQ ID NO: 24)

1 GAAGAAGTTT CTGAATATTG TAGCCACATG ATTGGGAGTG GACACCTGCA
51 GTCTCTGCAG CGGCTGATTG ACAGTCAGAT GGAGACCTCG TGCCAAATTA
101 CATTTGAGTT TGTAGACCAG GAACAGTTGA AAGATCCAGT GTGCTACCTT
151 AAGAAGGCAT TTCTCCTGGT ACAAGACATA ATGGAGGACA CCATGCGCTT
201 CAGAGATAAC ACCCCCAATG CCATCGCCAT TGTGCAGCTG CAGGAACTCT
251 CTTTGAGGCT GAAGAGCTGC TTCACCAAGG ATTATGAAGA GCATGACAAG
301 GCCTGCGTCC GAACTTTCTA TGAGACACCT CTCCAGTTGC TGGAGAAGGT
351 CAAGAATGTC TTTAATGAAA CAAAGAATCT CCTTGACAAG GACTGGAATA
401 TTTTCAGCAA GAACTGCAAC AACAGCTTTG CTGAATGCTC CAGCCAAGAT
451 GTGGTGACCA AGCCTGATTG CAACTGCCTG TACCCCAAAG CCATCCCTAG
501 CAGTGACCCG GCCTCTGTCT CCCCTCATCA GCCCCTCGCC CCCTCCATGG
551 CCCCTGTGGC TGGCTTGACC TGGGAGGACT CTGAGGGAAC TGAGGGCAGC
601 TCCCTCTTGC CTGGTGAGCA GCCCCTGCAC ACAGTGGATC CAGGCAGTGC
651 CAAGCAGCGG CCACCCAGG

A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) :C07H 21/04; C07K 13/00; C12N 1/00, 5/10, 15/62, 15/63
US CL :435/69.7, 240.1, 243, 320.1; 530/350; 536/23.4

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/69.7, 240.1, 240.2, 243, 252.3, 252.33, 254, 255, 256, 320.1; 530/350; 536/23.4; 935/44, 47

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
<u>X</u> Y	Biotechnol. Appl. Biochem., Volume 14, No. 3, issued December 1991, M. Murby <u>et al.</u> , "Stabilization of recombinant proteins from proteolytic degradation in <u>Escherichia coli</u> using a dual affinity fusion strategy", pages 336-346, Medline abstract No. 92134603	1-2, 5-8 3-4, 9-10
X	European Journal of Biochemistry, Volume 182, issued 1989, M. Kamo <u>et al.</u> , "Primary structure of spinach-chloroplast thioredoxin-f", pages 315-322, entire document.	1, 6-7
X	Biochemical and Biophysical Research Communications, Volume 155, No. 3, issued 30 September 1988, R.J. Boado <u>et al.</u> , "Nucleotide sequence of rat liver iodothyronine 5'-moniodinase (5'MD): its identity with the protein disulfide isomerase", pages 1297-1304, entire document.	1-2, 6-7

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	* " later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
* "A" document defining the general state of the art which is not considered to be part of particular relevance	* "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
* "E" earlier document published on or after the international filing date	* "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
* "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	* "G" document member of the same patent family
* "O" document referring to an oral disclosure, use, exhibition or other means	
* "P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

29 September 1993

Date of mailing of the international search report

OCT 07 1993

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Authorized officer

ROBERT A. WAX

Facsimile No. NOT APPLICABLE

Telephone No. (703) 308-0196

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	The EMBO Journal, Volume 6, No. 3, issued March 1987, T. Pihlajaniemi <u>et al.</u> , "Molecular cloning of the β -subunit of human prolyl 4-hydroxylase. This subunit and protein disulfide isomerase are products of the same gene", pages 643-649, entire document.	1-2, 6-7

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

APS, DIALOG files 155, 434, 5 (Medline, Scisearch, Biosis)

search trms: thioredoxin??, glutathione?? not glutathione transferase??, glutaredoxin??, phosphoinositide??, phospholipase?? c, erp72, erp 72, fusion protein??, fusion peptide??, chimera?, protein??, peptide??, galactosidase